By Counterforce Health Team in Cosentyx (secukinumab) —

How to Get Cosentyx (Secukinumab) Covered by UnitedHealthcare in North Carolina: Appeals Guide & Success Strategies

Answer Box: Getting Cosentyx Covered by UnitedHealthcare in North Carolina

UnitedHealthcare requires prior authorization for Cosentyx (secukinumab) with specific documentation of treatment failures and medical necessity. The fastest path: Have your dermatologist or rheumatologist submit a complete PA request with detailed records of failed first-line therapies. If denied, you have 180 days to appeal internally, then 120 days for North Carolina's Smart NC external review. Start today: Contact your prescriber to request the prior authorization and gather documentation of previous treatments.

Table of Contents

When UnitedHealthcare Alternatives Make Sense

Before diving into appeals, it's worth understanding when exploring UnitedHealthcare's preferred alternatives might be the right first step. UnitedHealthcare's OptumRx formulary typically requires step therapy for Cosentyx, meaning you'll need to try other biologics first unless you qualify for an exception.

Consider alternatives when:

  • You're newly diagnosed and haven't tried first-line biologics
  • Your current treatment isn't working but you haven't documented failure properly
  • You have specific contraindications that make Cosentyx risky
  • Time isn't critical and you're open to trying proven alternatives

Skip to Cosentyx appeals when:

  • You've failed multiple TNF inhibitors with proper documentation
  • You have contraindications to preferred alternatives
  • Your condition is rapidly worsening and needs immediate intervention
  • Previous biologics caused serious adverse effects

Typical Cosentyx Alternatives by Class

UnitedHealthcare's step therapy typically follows this progression for psoriasis and psoriatic arthritis:

TNF Inhibitors (Usually Required First)

Humira (adalimumab) and Enbrel (etanercept) are typically UnitedHealthcare's preferred first-line biologics. These have the longest track record and often receive formulary preference.

  • Advantages: Well-studied, effective for both skin and joint symptoms
  • Requirements: Standard TB screening, routine monitoring
  • Typical trial period: 3-6 months before considering failure

IL-23 Inhibitors (Growing Preference)

Skyrizi (risankizumab) and Tremfya (guselkumab) are gaining formulary favor due to their safety profiles and dosing convenience.

  • Advantages: Excellent skin clearance, fewer infections than TNF inhibitors
  • Requirements: Minimal monitoring compared to other biologics
  • Dosing: Less frequent injections (every 12 weeks for maintenance)

Other IL-17 Inhibitors

Taltz (ixekizumab) is Cosentyx's main competitor in the IL-17 class and may be preferred on some UnitedHealthcare formularies.

  • Advantages: Similar efficacy to Cosentyx, rapid onset
  • Requirements: Same monitoring as Cosentyx
  • Key difference: Different injection schedule and device

Pros and Cons of Alternative Options

Alternative Class Access Advantages Testing Requirements Monitoring Needs
TNF Inhibitors Usually preferred tier, established PA pathways TB screening, hepatitis panel Regular labs, infection screening
IL-23 Inhibitors Growing formulary preference, excellent safety Minimal baseline screening Minimal ongoing monitoring
Other IL-17 Inhibitors Similar to Cosentyx, may be preferred TB screening recommended Similar to Cosentyx

Access considerations:

  • TNF inhibitors often have the most streamlined approval process
  • IL-23 inhibitors are increasingly favored by payers for their safety profile
  • Switching between IL-17 inhibitors (like Taltz to Cosentyx) may require additional justification

Exception Strategy for Cosentyx

When you need to skip step therapy and go directly to Cosentyx, your exception request must address UnitedHealthcare's specific medical necessity criteria.

Key Documentation Requirements

Diagnosis confirmation:

  • Specialist consultation notes from dermatology or rheumatology
  • Specific ICD-10 codes for your condition
  • Objective disease severity measures (PASI score, joint counts, imaging results)

Treatment failure documentation:

  • Names, doses, and duration of previous therapies
  • Specific reasons for discontinuation (lack of efficacy, adverse effects, contraindications)
  • Clinical notes showing inadequate response after appropriate trial periods

Medical necessity justification:

  • Why Cosentyx is specifically needed over alternatives
  • Clinical guidelines supporting IL-17 inhibitor use for your condition
  • Any unique patient factors (comorbidities, drug interactions, injection preferences)

Evidence That Strengthens Appeals

According to UnitedHealthcare's medical policy, successful Cosentyx approvals typically include:

  • Documentation of 3+ month trials of conventional therapies
  • Specialist attestation of disease severity
  • Clear contraindications or failures of preferred alternatives
  • Objective measures of disease activity (labs, imaging, validated scales)
From our advocates: We've seen the strongest exception approvals when specialists provide a detailed timeline of previous treatments, including specific reasons each therapy was inadequate. A simple "patient failed methotrexate" isn't enough—document the dose, duration, side effects, and objective measures of continued disease activity.

Switching Logistics and Provider Coordination

If you're currently on another biologic and switching to Cosentyx, coordination between your healthcare team and pharmacy benefits is crucial.

No Washout Period Required

Current evidence shows that switching from biologics like Humira, Enbrel, or Stelara to Cosentyx typically doesn't require a washout period. However, your provider should coordinate the transition to avoid disease flares.

Monitoring During Transition

Required monitoring when switching to Cosentyx:

  • Baseline TB screening (interferon-gamma release assay preferred)
  • Complete blood count and liver function tests at 4 weeks, then every 3-6 months
  • Hepatitis B and C screening if risk factors present

Pharmacy Benefit Coordination

Before switching:

  1. Verify Cosentyx's formulary status on your specific UnitedHealthcare plan
  2. Confirm site-of-care requirements (some plans require specialty pharmacy)
  3. Submit prior authorization with switching rationale
  4. Coordinate with your specialty pharmacy for seamless transition

Counterforce Health can help streamline this process by analyzing your specific UnitedHealthcare policy and preparing targeted appeals that address the exact criteria your plan requires for Cosentyx approval.

Re-trying for Cosentyx Later

If you try an alternative first and it doesn't work, documenting the trial properly sets you up for a stronger Cosentyx appeal later.

What to Document During Alternative Trials

Objective measures:

  • Baseline and follow-up PASI scores for psoriasis
  • Joint counts and functional assessments for psoriatic arthritis
  • Laboratory markers (CRP, ESR) if relevant
  • Patient-reported outcomes and quality of life measures

Treatment details:

  • Exact medication name and NDC number
  • Dosing schedule and any dose adjustments
  • Duration of therapy and reasons for discontinuation
  • Any adverse effects, even minor ones

Clinical progression:

  • Regular photo documentation of skin lesions
  • Functional assessments for joint symptoms
  • Work or activity limitations due to inadequate response

This documentation becomes powerful evidence when you later appeal for Cosentyx, showing you gave the alternative a fair trial but still need the more targeted therapy.

Appeals Playbook for North Carolina

North Carolina offers robust appeal rights through both internal insurer processes and the state's Smart NC external review system.

Internal Appeals with UnitedHealthcare

Level 1 Internal Appeal:

  • Timeline: 180 days from denial notice
  • Decision timeframe: 30 days for standard, 72 hours for urgent
  • Submission: UnitedHealthcare member portal or mail to address on denial letter
  • Required documents: Completed appeal form, medical records, physician letter

Level 2 Internal Appeal:

  • Timeline: 60 days from Level 1 denial
  • Decision timeframe: 30 days for standard
  • Additional option: Peer-to-peer review with medical director

North Carolina Smart NC External Review

If UnitedHealthcare upholds their denial, North Carolina's Smart NC program provides independent review.

Eligibility:

  • Fully insured UnitedHealthcare plans (not self-funded employer plans)
  • Denial based on medical necessity or experimental treatment determination
  • Completed internal appeals process

Process:

  1. Submit request: Within 120 days of final internal denial
  2. Preliminary review: Smart NC determines eligibility
  3. Independent review: Assigned to Independent Review Organization (IRO)
  4. Decision: Within 45 days (72 hours for expedited cases)

Contact Smart NC: 1-855-408-1212 for free advocacy assistance

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
Step therapy not completed Document contraindications or failures of preferred agents Previous treatment records, adverse effect notes, specialist letter
Insufficient medical necessity Provide objective disease severity measures PASI scores, joint counts, lab values, imaging results
Missing TB screening Complete required screening IGRA or tuberculin skin test results, chest X-ray
Inadequate specialist involvement Obtain specialist consultation Dermatology or rheumatology consultation notes
Quantity limits exceeded Justify higher dosing or frequency Clinical guidelines, FDA labeling, specialist recommendation

FAQ

How long does UnitedHealthcare prior authorization take in North Carolina? Standard prior authorization decisions are typically made within 72 hours for urgent requests and 15 days for non-urgent requests. Appeals take 30 days for standard reviews.

What if Cosentyx is non-formulary on my UnitedHealthcare plan? Non-formulary drugs can still be covered through medical exception requests. You'll need stronger documentation showing why formulary alternatives are inappropriate for your condition.

Can I request an expedited appeal for Cosentyx? Yes, if delaying treatment could seriously jeopardize your health or ability to regain function. Rapidly progressive psoriatic arthritis or severe psoriasis may qualify for expedited review.

Does step therapy apply if I failed biologics outside North Carolina? Treatment history from other states counts toward step therapy requirements. Ensure your new North Carolina provider has complete records of previous treatments and outcomes.

What's the success rate for Cosentyx appeals in North Carolina? While specific success rates aren't published, appeals with complete clinical documentation and clear medical necessity have significantly higher approval rates. Smart NC's external review process provides an additional avenue when internal appeals fail.

How much does Cosentyx cost with UnitedHealthcare coverage? Costs vary by plan, but specialty biologics typically fall on higher formulary tiers. Novartis offers copay assistance programs that may reduce out-of-pocket costs for eligible patients.

This information is for educational purposes only and doesn't constitute medical or legal advice. For personalized guidance on your specific situation, consult with your healthcare provider and insurance representative.

Need help with your UnitedHealthcare appeal? Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Our platform analyzes your specific policy requirements and drafts point-by-point rebuttals that align with UnitedHealthcare's own rules, helping patients get the medications they need.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.